A novel Rift Valley fever vaccine
- PMID: 37060918
- DOI: 10.1016/S1473-3099(23)00134-2
A novel Rift Valley fever vaccine
Conflict of interest statement
MS is an Investigator for Biotest; receives consulting fees from Biotest, Merck Sharp & Dohme, and Takeda; receives honoraria from Biotest, Merck Sharp & Dohme, Takeda, Novartis, and Qiagen; receives support for attending meetings and travel from Biotest and Takeda; is a member of Data Safety Monitoring Boards or Advisory Boards for Biotest, Takeda, and Moderna; and is a member of the Tuberculosis Network European Trials group Steering Committee. SB declares no competing interests.
Comment on
-
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.Lancet Infect Dis. 2023 Aug;23(8):956-964. doi: 10.1016/S1473-3099(23)00068-3. Epub 2023 Apr 13. Lancet Infect Dis. 2023. PMID: 37060917 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
